Thus, this study aims to analyze the role of ALDH1A2, ALDH3A1, and ALDH16A1 genetic variability in MDS and AML development and progression, in order to identify new potential risk factors and/or prognostic markers. Here, ALDH16A1 is linked to acute myeloid leukemia.